Apollomics, Inc. (NASDAQ:APLM) Short Interest Down 98.3% in November

Apollomics, Inc. (NASDAQ:APLM) saw a large drop in short interest during the month of November. As of November 15th, there was short interest totalling 2,900 shares, a drop of 98.3% from the October 31st total of 168,500 shares. Based on an average daily volume of 283,800 shares, the short-interest ratio is currently 0.0 days.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Apollomics stock. George Kaiser Family Foundation grew its position in Apollomics, Inc. (NASDAQ:APLM) by 2,585.6% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 670,976 shares of the company’s stock after acquiring an additional 645,992 shares during the period. Apollomics comprises 0.0% of George Kaiser Family Foundation’s portfolio, making the stock its 18th largest holding. George Kaiser Family Foundation owned 0.75% of Apollomics worth $141,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 19.13% of the company’s stock.

Apollomics Stock Performance

Apollomics stock remained flat at $8.16 during midday trading on Wednesday. 70,433 shares of the company’s stock traded hands, compared to its average volume of 92,573. Apollomics has a 52 week low of $7.55 and a 52 week high of $118.00. The business has a 50-day moving average price of $13.03 and a 200 day moving average price of $17.48.

Apollomics Company Profile

Apollomics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company’s products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain.